Browse: Companies | People | Financial Organizations
Home > Companies > Synosia Therapeutics

General Information

Websitesynosia.com
CategoryBioTech
Email
Employees
DescriptionPharmaceutical Compounds

Offices

Headquarters
Aeschenvorstadt 36
CH-4051
Basel, CHE

People

CEO & President
CFO

Funding

Tags

Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson’s disease.

Milestones

Videos

Screenshots

Sources

  1. Synosia raises $29M for Phase II testing (fiercebiotech.com) [edit]
  2. Neurological co. Synosis raises $32.5M (deals.venturebeat.com) [edit]
Edit This Page
Last Edited 9/16/09

Revision History RSS Picture

External Links

Embed Widget

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy